PYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64mood

MRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10mood

RBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47mood

GLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31mood

GE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04mood

MELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88mood

ETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35mood

PD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08mood

COST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44mood

ENSC · Ensysce Biosciences, Inc. — sentiment, insiders, filings

ENSC

ENSCEnsysce Biosciences, Inc.

Discussion

Nothing said here yet.

to join the conversation.

GOWER BOB GDirector

Buy

400,000

$198.0K

Fri, Aug 7

GOWER BOB GDirector

Buy

508,614

$246.2K

Thu, Apr 23

Thu, Aug 20
7:00 AMYahooEnsysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
Fri, Aug 14
7:12 AMYahooENSC Sets Itself Up Nicely for Critical Stage
Thu, Aug 13
3:15 PMYahooEnsysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Thu, Aug 6
9:50 AMinvestorshub.advfn.comEnsysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing
7:00 AMYahooEnsysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
6:25 AMYahooENSC Makes Bold Move that Bolsters Pipeline and Finances
Tue, Jul 14
9:45 AMinvestorshub.advfn.comEnsysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development
7:00 AMYahooEnsysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
6:58 AMYahooENSC Receives Vital Funding for Drive to Commercialization
Thu, Jul 9
9:41 AMYahooPostoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics
Fri, Jun 26
7:00 AMYahooEnsysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Mon, May 18
6:04 AMYahooENSC Advancing Testing and Expanding Potential